Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2022 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219

BMF-219 is the first menin inhibitor to reach the clinic for type 2 diabetes. The Phase II portion of COVALENT-111 is designed to examine the capacity of BMF-219 to provide long-term glycemic control...
October 27, 2022 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial

COVALENT-101 now includes patients with relapsed/refractory (R/R) CLLBMF-219 is the first menin inhibitor in the clinic for CLLPreclinical data presented at ASCO 2022 demonstrated the potency of...
October 14, 2022 09:00 ET | Source: Biomea Fusion, Inc.

BMF-219 Enters the Clinic for KRAS Solid Tumors

Biomea Fusion announces FDA clearance of Investigational New Drug (IND) application for covalent menin inhibitor BMF-219 in KRAS solid tumors.Biomea Fusion will now initiate a Phase I/Ib clinical...
September 22, 2022 09:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

Treatment with BMF-219 led to an increase in beta cell mass in ex-vivo experiments with human donor isletsBMF-219 showed improved pancreatic beta-cell function and beta cell area, insulin sensitivity,...
September 20, 2022 07:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes

Menin, a transcriptional scaffold protein, regulates pancreatic beta cell homeostasis; inhibiting menin function with BMF-219 increased beta cell function in a preclinical animal model, driving an...
August 26, 2022 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting

Data demonstrated robust anti-tumor activity of BMF-219 and mechanistic evidence for novel inhibition of menin protein in preclinical models of Diffuse Large B-cell Lymphoma (DLBCL) and multiple...
August 01, 2022 16:05 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Reports Second Quarter 2022 Financial Results and Business Highlights

Continued to make significant progress advancing BMF-219, the company’s lead investigational orally administered covalent menin inhibitor, in multiple oncology indications COVALENT-101 (Phase I) study...
July 01, 2022 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes

Biomea to present two oral abstracts across multiple animal models highlighting the ability of BMF-219, a covalent menin inhibitor, to significantly lower HbA1C (approximately two-fold greater...
June 22, 2022 08:30 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial

BMF-219, a covalent menin inhibitor, is the first menin inhibitor administered to patients with relapsed/refractory (R/R) multiple myeloma (MM)Patients with R/R MM and R/R diffuse large B-cell...
June 04, 2022 11:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

Menin acts as a ‘brake’ on beta cell regeneration; inhibiting menin function with BMF-219 may increase beta cell production and function, thereby increasing insulin levels and controlling high glucose...